Multiple Sclerosis Treatments: An Overview of Injections and Infusions
Multiple Sclerosis (MS) is a debilitating disease affecting over 2.8 million people worldwide. This condition targets the central nervous system, including the brain and spinal cord, causing a range of symptoms that vary between individuals and depend on the areas affected.
In MS, the immune system mistakenly attacks the myelin sheath, a fatty material that surrounds and protects nerves. This attack leads to inflammation, damage, and scarring in the affected areas, disrupting the transmission of signals along the nerves.
To combat this disease, a variety of treatment options are available, each with its own advantages and considerations in terms of effectiveness, administration frequency, and side effects.
Effectiveness
All treatment options for MS include disease-modifying therapies (DMTs) that vary in efficacy but generally aim to reduce MS activity and disability progression. Infusion treatments such as Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) are considered highly effective for relapsing MS and show similar effectiveness in reducing disease activity and slowing progression.
Oral DMTs have been increasingly used since 2010 and offer a range of efficacy levels, but recent trends show a shift towards more frequent use of higher-efficacy infusion and injectable therapies.
Administration Frequency
Oral therapies are generally administered daily or with varying daily schedules, depending on the drug. Injectable therapies like Kesimpta involve monthly subcutaneous injections that patients can self-administer at home. Infusion therapies such as Ocrevus require administration by IV infusion, typically every six months, although a subcutaneous infusion called Ocrevus Zunovo is shorter, at about 55 minutes to 1 hour 40 minutes.
Side Effects and Patient Convenience
Infusions often require clinical setting, pre-infusion preparation, monitoring for reactions, and more time commitment per session. Subcutaneous infusion of Ocrevus Zunovo improves convenience and reduces discomfort compared to traditional IV infusions. Monthly injections can be self-administered, offering convenience, though there may be localized injection reactions.
Oral medications generally offer maximum convenience but may have systemic side effects depending on the specific drug. Both Ocrevus and Kesimpta share similar side effect profiles related to immune suppression, including lower immunoglobulin G (IgG) levels after switching between them, which may impact infection risk and requires monitoring.
Summary
In conclusion, infusion therapies provide very high efficacy but at the cost of longer and less frequent administrations in clinical settings, while injections offer a more convenient monthly schedule with similar efficacy. Oral therapies are the most convenient but generally have a wider range of efficacy and side effect profiles. Patient preference, disease severity, and lifestyle considerations often guide therapy choice.
It is crucial to note that further research is needed to assess the long-term effects of oral disease-modifying therapies, as their use has become more prevalent in recent years.
References:
- Ocrevus (ocrelizumab) Summary for Patients and Carers
- Kesimpta (ofatumumab) Summary for Patients and Carers
- Multiple Sclerosis: A Review of Current Treatment Options
- Disease-modifying therapies for multiple sclerosis
- Switching between Ocrevus and Kesimpta does not affect effectiveness
- Multiple Sclerosis (MS) is a neurological disorder that affects over 2.8 million people worldwide, targeting the central nervous system and causing a range of symptoms related to medical-conditions.
- This condition involves the immune system attacking the myelin sheath, which leads to inflammation, damage, and scarring in the affected areas of the brain and spinal cord.
- To manage MS, multiple therapies and treatments are available, including disease-modifying therapies (DMTs) that aim to reduce MS activity and disability progression.
- Infusion treatments like Ocrevus and Kesimpta are highly effective for relapsing MS, offering similar effectiveness in reducing disease activity and slowing progression, but they require administration in a clinical setting and have longer administration times.
- Oral DMTs are increasingly used, but their efficacy can vary, and they may have systemic side effects depending on the specific drug. Oral medications like Ocrevus and Kesimpta share similar side effect profiles related to immune suppression.
- Further research is needed to assess the long-term effects of oral disease-modifying therapies as their use has become more prevalent in recent years, especially with regard to health-and-wellness aspects like infection risk.
(References omitted for brevity)
